Pharmacogenomics studies how genetic variants can affect the way a person processes or responds to certain medications. For some gene-drug pairs, the evidence is strong enough to guide dosing or drug selection; for others, the evidence is limited and a test result should not be treated as a prediction of whether a medication will work.
Last reviewed by Mary Margaret Burch, FNP-BC, FMAPS — September 2026
Medication trial-and-error can be exhausting. A child may become activated, sedated, irritable, or simply get no benefit. After several attempts, a genetic test that promises to identify the “right medication” sounds like a relief.
Pharmacogenomics is real science, but the marketing around it can run ahead of the evidence. Some genetic variants meaningfully affect how the body metabolizes specific drugs. That can help a prescriber avoid unusually high or low exposure. It is different from predicting the entire clinical response.
Think of it as knowing how fast a sink drains. That information helps you estimate how quickly water may build up. It does not tell you whether the water itself is the right temperature, whether the faucet works, or whether the person using the sink likes the result.
Pharmacogenomic guidance works best when a particular gene has been studied with a particular medication. For some antidepressants, genes such as CYP2D6 and CYP2C19 can affect drug metabolism. The Clinical Pharmacogenetics Implementation Consortium publishes guidance for some of these relationships.
But not every gene printed on a commercial psychiatric panel has enough evidence to guide treatment. CPIC, for example, does not provide prescribing recommendations for some commonly marketed serotonin-related genes because evidence is mixed or insufficient.
Pediatric evidence also matters. Children and adolescents are underrepresented in many pharmacogenomic studies, so a result that is useful in adults may need more cautious interpretation in a child.
If this framework is clicking for you and you’re tired of piecing things together from random posts and forums, consider joining the Spectrum Care Hub Learning Community. You’ll get full access to step-by-step biomedical coursework, printable tools, and new lessons added every month. Learn more →
A 2025 retrospective study of high-acuity behavioral health care in autism found that pharmacogenomic testing changed some prescribing patterns, but it did not improve the measured quality-of-life or symptom outcomes compared with treatment as usual. That is an important kind of result because it keeps expectations realistic.
The lesson is not that pharmacogenomics is useless. It is that a test is one piece of medication management. Diagnosis, target symptom, dose, timing, interactions, sleep, pain, gastrointestinal problems, and the child’s prior response history all still matter.
A clinician may be more interested in pharmacogenomic information when a patient has had unusual side effects at low doses, repeated unexpected medication responses, several failed medication trials, or a medication under consideration that has established gene-based guidance.
Even then, the question should be specific: “Would this result change what you prescribe or how you dose it?” If the answer is no, the test may not be the best next expense.
If your child already has pharmacogenomic results, bring the full report and medication history to the prescriber. Do not stop or change medication because a report labels a drug red, yellow, or green. Those categories simplify complex evidence and may not account for the reason the drug was prescribed, other medications, age, or clinical response.
If you are considering testing, ask whether the medication in question has an established gene-drug guideline and whether the result would change prescribing. That keeps the test connected to a real decision.
This section is for education only. These are examples of questions you might consider raising with your healthcare provider. They are not instructions for self-directed intervention.
Why this works: It separates evidence-based gene-drug relationships from broad commercial panel claims.
Why this works: It makes actionability the standard for deciding whether the test is worth the cost.
Why this works: Pediatric evidence can be more limited than adult evidence.
Why this works: A real response history can be as important as a predicted metabolism category.
If this helped you see your child’s behavior and biology in a new light, the next step is to keep building on that clarity. Our Spectrum Care Hub subscription gives you the complete course library, deeper dive modules, and ongoing support, so you don’t have to navigate autism and PANS/PANDAS care alone. Join the learning community →
Not reliably. Some tests can identify metabolism differences for certain medications, but they cannot predict the full clinical response or guarantee benefit.
They are genes that encode liver enzymes involved in metabolizing many medications. Variants can make some people process certain drugs more slowly or more quickly.
They may be useful for specific medication questions, but evidence is still limited for many outcomes in autism. Testing should be tied to a medication with meaningful gene-drug evidence.
No. Do not stop or change a prescribed medication based on a report without speaking with the prescriber. The report may reflect metabolism or evidence categories that need clinical interpretation.
No. Side effects, target symptoms, sleep, appetite, behavior, other medications, and dose changes still need to be monitored closely.
No. Pharmacogenomics focuses on gene-drug relationships. Broad wellness or nutrigenomic reports cover many other pathways and often have a different evidence base.
This article is for educational purposes only. It does not constitute medical advice and does not create a provider-patient relationship between the reader and Mary Margaret Burch, FNP-BC, FMAPS, or Spectrum Care Hub LLC. Do not use this article to self-diagnose, self-treat, or make decisions about your child’s care without consultation with a qualified, licensed healthcare provider. Do not start, stop, or change any treatment, medication, supplement, or therapeutic intervention based on this content alone.
Individual children vary significantly in their biology, presentation, and response to interventions. Research findings describe groups and do not predict what will happen for any individual child.
Last reviewed by Mary Margaret Burch, FNP-BC, FMAPS — September 2026.
© 2026 Spectrum Care Hub LLC. All rights reserved. Content is protected under 17 U.S.C. § 101 et seq. Personal, non-commercial use only. Unauthorized reproduction or redistribution is prohibited.